March 27, 2025 - 00:31

Stocks are on shifting sands as markets respond to changes in tone from Trump on coming tariffs. The Nasdaq and S&P 500 experienced significant declines, breaking their three-day winning streak amid growing concerns over potential auto tariffs. Investors are closely monitoring the situation, as the prospect of new tariffs could have far-reaching implications for various sectors, particularly the automotive industry.
Market analysts suggest that uncertainty surrounding trade policies is contributing to the volatility. As discussions around tariffs escalate, many traders are reassessing their positions, leading to a wave of selling. The impact of these tariffs could ripple through the economy, affecting supply chains and consumer prices.
In light of these developments, investors are urged to stay informed and consider the broader economic implications of the proposed tariffs. With the market reacting swiftly to news, it remains crucial for stakeholders to navigate this shifting landscape with caution.
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...